Min Zhong

Founder at QILU Regor Therapeutics, Inc.

Commercial Services

Profile

Min Zhong has founded QILU Regor Therapeutics, Inc. in 2018, where he holds the title of Chief Operating Officer.
He is currently the Chief Operating Officer at Regor Therapeutics Group.

Min Zhong active positions

Companies	Position	Start
Regor Therapeutics Group Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu.	Chief Operating Officer	-
QILU Regor Therapeutics, Inc.	Founder	31/12/2017

All active positions of Min Zhong

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Min Zhong's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Regor Therapeutics Group Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu.	Commercial Services
QILU Regor Therapeutics, Inc.